Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.

Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2- breast cancer. We sought to evaluate the impact of everolimus-based therapy on overall survival in the ESME-MBC database, a national metastatic breast cancer cohort that collects retrospective data using clinical trial-like methodology including quality assessments. We compared 1693 patients having received everolimus to 5928 patients not exposed to everolimus in the same period. Overall survival was evaluated according to treatment line, and a propensity score with the inverse probability of treatment weighting method was built to adjust for differences between groups. Crude and landmark overall survival analyses were all compatible with a benefit from everolimus-based therapy. Adjusted hazard ratios for overall survival were 0.34 (95% CI: 0.16-0.72,

Déclaration de conflit d'intérêts

JSF declares consulting fees from Pfizer, Lilly, Novartis, AstraZeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, Seagen, Exact Science; honoraria for lectures from Lilly, Novartis, Gilead, Daiichi Sankyo, Seagen; travel support and meeting attendance from Pfizer, Milly, Novartis, AstraZeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, Seagen. AG declares Institutional research funding from MSD, BMS, Novartis, Boehringer Ingelheim, Roche Genentech, AstraZeneca, Sanofi, and Daiichi Sankyo. PC declares consulting fees and honoraria from Pfizer, Roche, Lilly; Institutional research funding from Novartis, Pfizer; travel support and meeting attendance from Roche, Pfizer, and Daiichi Sankyo. All other authors declare no conflicts of interest.